Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

The FDA has provided no comments on a study protocol submitted in August 2026, including its primary endpoints and planned enrollment of approximately 325 patients. A central U.S. ethics committee approved the protocol and consent documents; first-patient enrollment is still expected, though the timing is cut off in the article text.